Theratechnologies Inc. (TH) Stock Price Down 2.3% Following Analyst Downgrade
Theratechnologies Inc. (TSE:TH) shares dropped 2.3% during trading on Tuesday after National Bank Financial lowered their price target on the stock from C$9.75 to C$8.75. National Bank Financial currently has an outperform rating on the stock. Theratechnologies traded as low as C$7.30 and last traded at C$7.33. Approximately 78,814 shares changed hands during mid-day trading, a decline of 48% from the average daily volume of 152,934 shares. The stock had previously closed at C$7.50.
Separately, Scotiabank reduced their target price on Theratechnologies from C$10.00 to C$9.25 and set an “outperform” rating on the stock in a research note on Friday, October 6th.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/theratechnologies-inc-th-stock-price-down-2-3-following-analyst-downgrade/1703634.html.
Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.
Receive News & Ratings for Theratechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.